A novel treatment target for Parkinson's disease

@article{Wakade2014ANT,
  title={A novel treatment target for Parkinson's disease},
  author={Chandramohan Wakade and Raymond Chong},
  journal={Journal of the Neurological Sciences},
  year={2014},
  volume={347},
  pages={34-38}
}
We hypothesize that GPR109A message and expression are up-regulated in individuals with Parkinson's disease (PD). GPR109A is a high-affinity niacin receptor. Niacin is a precursor for NAD-NADH which is needed for dopamine production. Thus, niacin supplementation may serve three purposes: reduce inflammation through GPR109A-related mechanisms, increase dopamine synthesis in the striatum through NADPH supply and increase NAD/NADH ratio to boost mitochondrial functions. GPR109A and its agonists… Expand
Niacin modulates macrophage polarization in Parkinson's disease
TLDR
It is reported that lower dose of niacin in PD patients may affect macrophage polarization from M1 (pro-inflammatory) to M2 (counter- inflammatory) profile through the niacIn receptor GPR109A. Expand
Vitamin B3: niacin and transcriptome analysis in relation to the GPR109A receptor
TLDR
The antiinflammatory role of GPR 109A has been demonstrated in many different tissue types, potentially improving disease states from Parkinson’s disease to diabetic retinopathy and its impact on colon and breast cancer suggests that GPR109A functions as a tumor suppressor. Expand
Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson’s disease mice model
TLDR
The combination of curcumin, niacin and ZM 241385 recorded the most potent treatment effect in Parkinsonism mice followed by ZM241385, as a single treatment, which succeeded to antagonize adenosine A2A receptor by diminishing its gene expression and ameliorating all biochemical parameters under investigation. Expand
Emerging preclinical pharmacological targets for Parkinson's disease
TLDR
Various emerging preclinical pharmacological targets that may serve as a new promising neuroprotective strategy that could actually help alleviate Parkinson's disease and its symptoms are discussed. Expand
Preventive treatments to slow substantia nigra damage and Parkinson's disease progression: a critical perspective review.
TLDR
Novel drug targets that should be targeted to slow PD progression are reviewed, clinical and experimental research data reporting new treatments targeting immune-inflammatory and oxidative pathways are reported, and future research should clarify the efficacy, and interactions, of nicotine receptor agonists, gut microbiome-derived butyrate, melatonin, and NSAIDs in the treatment of PD. Expand
Niacin for Parkinson's disease
TLDR
Clinical trials and the role of niacin in reducing neuroinflammation in PD are presented and available clinical trials show the importance of this molecule in delaying progression and reducing damage by inflammatory molecules in PD patients. Expand
Niacin Enhancement for Parkinson’s Disease: An Effectiveness Trial
TLDR
An effectiveness trial to determine the effect of 12 months of low-dose niacin (a vitamin B3 derivative) enhancement in PD individuals and suggest that niacIn enhancement has the potential to maintain or improve quality of life in PD and slow disease progression. Expand
Prevention of progression in Parkinson’s disease
  • J. Aaseth, P. Dušek, P. Roos
  • Medicine
  • Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine
  • 2018
TLDR
Recent research indicates that the substantia nigra degeneration can be decelerated by treatment with iron binding compounds such as deferiprone, and compounds known to decrease PD risk including caffeine, niacin, nicotine and salbutamol also possess iron binding properties. Expand
Shared perturbations in the metallome and metabolome of Alzheimer’s, Parkinson’s, Huntington’s, and dementia with Lewy bodies: A systematic review
TLDR
Findings indicate that disturbances in glucose and purine pathways may be common to AD, PD, and HD, however, standardisation of methodologies and better coverage in some areas - notably of DLB - are necessary to validate and extend these findings. Expand
Niacin receptor GPR109A inhibits insulin secretion and is down-regulated in type 2 diabetic islet beta-cells.
TLDR
Results demonstrate that GPR109A is functionally expressed in both human and murine islet beta-cells, and the role of GPR 109A in the prevention of diabetes or insulinoma needs further study. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 47 REFERENCES
Novel anti-inflammatory therapy for Parkinson's disease.
TLDR
Growing experimental evidence demonstrates that inhibition of the inflammatory response can, in part, prevent degeneration of nigrostriatal dopamine-containing neurons in several animal models of PD, suggesting that inhibitionof inflammation might become a promising therapeutic intervention for PD. Expand
Neuroinflammatory processes in Parkinson's disease
TLDR
It is proposed that, in PD, neuroinflammation plays a role in the cascade of events leading to nerve cell death, thus propagating the neurodegenerative process. Expand
Mitochondrial metabolism modulation: a new therapeutic approach for Parkinson's disease.
TLDR
This review will focus on mitochondrial metabolic control and its implications on sirtuins activation, microtubule dynamics and autophagic-lysosomal pathway and address mitochondrial metabolism modulation as a new promising therapeutic tool for PD. Expand
Broad neuroprotective profile of nicotinamide in different mouse models of MPTP‐induced parkinsonism
TLDR
Results show neuroprotective effects of Nicotinamide in different mouse Parkinson models associated with different forms of cell death and suggest that nicotinamide may have broad neuroProtective potential in PD. Expand
Neuroinflammatory processes in Parkinson's disease. Discussion
TLDR
It is proposed that, in PD, neuroinflammation plays a role in the cascade of events leading to nerve cell death, thus propagating the neurodegenerative process. Expand
Niacin stimulates adiponectin secretion through the GPR109A receptor.
TLDR
Results demonstrate that the GPR109A receptor plays an important role in the dual regulation of adiponectin secretion and lipolysis. Expand
The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
TLDR
Recent progress in understanding the physiological and pharmacological role of the nicotinic acid receptor is summarized and its potential use as a new target for the development of antidyslipidemic drugs to prevent and treat cardiovascular diseases is discussed. Expand
High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease
TLDR
Nicotinamide at a relatively higher concentration significantly protected SK‐N‐MC human neuroblastoma cells from an MPP+‐induced decrease in cell viability, complex I and α‐ketoglutarate dehydrogenase activity, and an increase in oxidant generation, DNA damage, and protein oxidation. Expand
Control of mitochondrial integrity in Parkinson's disease.
TLDR
The role of mitochondria in the aetiology of PD has been questioned for decades, mostly from the perspective of bioenergetic failure, but it has been discovered that mutations in the genes encoding for Parkin, PINK1, PTEN-induced putative kinase-1 and DJ-1 are associated with familial forms of PD and with mitochondrial alterations, including morphological abnormalities. Expand
GPR109A as an anti-inflammatory receptor in retinal pigment epithelial cells and its relevance to diabetic retinopathy.
TLDR
It is speculated that the increased expression of GPR109A and elevation of its ligand β-HB in diabetes are mechanisms by which the tissue attempts to fight inflammation in this disease. Expand
...
1
2
3
4
5
...